Navigation Links
Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results
Date:2/13/2009

WEIFANG, Shandong, China, Feb. 13 /PRNewswire-Asia-FirstCall/ -- Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai" or "the Company"), a leading manufacturer and distributor of high-quality, pharmaceutical grade glucose products in China, today reported financial results for the second quarter of fiscal 2009 ended December 31, 2008.

"Sales of our glucose products increased during the second quarter compared with the September quarter," said Mr. Qingtai Liu, Shengtai Pharmaceutical's CEO. "Sales of our cornstarch and other products were impacted in the second quarter due to lower demand from the food and beverage sector along with slower economic growth. We believe that the solid demand for glucose products and the increased healthcare spending included in the Chinese government's recently approved 850 billion RMB healthcare reform plan, will propel the continued growth of our domestic glucose business. With the growth of our higher-margin glucose business, we look to consume more cornstarch internally to feed our glucose production, as our cornstarch plant directly connects into our glucose plant through pipes, eliminating shipping, lowering manufacturing costs and ensuring quality. Furthermore, we are pleased to see the declining corn prices in recent months, which will help improve our margins."

"On the sales front, our sales team is aggressively seeking new strategic partnerships, both domestically and internationally, to increase our market share and expand sales channels. In the midst of healthcare reform including new hospital build-out and increased healthcare budgets, many of our key customers are actively launching new products including higher margin non-PVC soft packaging transfusion products. We continue to engage with our current customers in an effort to increase their purchase volumes, as we seek to better understand their current procurement needs and new product develop
'/>"/>

SOURCE Shengtai Pharmaceutical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008
2. Shengtai Pharmaceutical, Inc. Appoints New CFO
3. Shengtai Pharmaceutical Retains Grayling Global As Investor Relations Counsel
4. Shengtai Pharmaceutical Completes Factory Improvements Resulting in Operational and Environmental Benefits
5. Shengtai Pharmaceutical Schedules 2009 First Quarter Financial Results and Conference Call
6. DOV Pharmaceutical, Inc. Begins Trading on OTC Bulletin Board
7. Mindray to Present at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
9. Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
10. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
11. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
(Date:12/22/2014)... -- GenomeDx Biosciences today announced that a new study ... test for prostate cancer, was able to predict rapid ... prostatectomy without adjuvant therapy. Although rapid metastasis in men ... genomics to identify these men who have a highly ... The study has been published online by the ...
(Date:12/22/2014)... ITRA Global, one of the largest organizations dedicated ... has further expanded its global reach with the affiliation ... Australia, reports Mylinda Vick, CCIM, Chairman of the ITRA ... ACORPP (Australian Corporate Property and Projects) , is a ... to a wide range of clients in the private ...
(Date:12/19/2014)... Charm Sciences is pleased to announce that ... Aflatoxin M1 in raw commingled milk is the first ... The peer reviewed report of the validation by Technology ... and Fisheries Research (ILVO-T&V) has been published by the ... most toxic aflatoxin and a known carcinogen, can be ...
Breaking Biology Technology:Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2
... 23, 2011 Genesis Biopharma, Inc. (OTC.BB:GNBP), a biotechnology ... California Governor, Gray Davis, has joined the company as ... committed to the improvement of healthcare and advancement of ... California became a leader in stem cell research as ...
... Syngenta announced today that it plans to construct a ... research campus in Research Triangle Park, North Carolina. The ... June 2011, will focus on discovering and developing new ... the world.   "This investment demonstrates ...
... May 20, 2011 Dendreon Corporation (Nasdaq: DNDN ) ... ThinkEquity Annual Healthcare Conference in New York City, NY ... Annual Global Healthcare Conference in Rancho Palos Verdes, CA on June ... presentations will be webcast live and available for replay from Dendreon,s ...
Cached Biology Technology:Governor Gray Davis Joins Genesis Biopharma as Chairman of Corporate Advisory Board 2Syngenta to Invest in New U.S. Genetics Research Facility 2
(Date:12/11/2014)... 2014  Data Sciences International (DSI), the global ... new series of digital telemetry implants to meet ... series, part of the PhysioTel™ Digital platform, was ... physiologic data when incorporating functional endpoints into repeat-dose ... toxicology studies has evolved from short ECG strips ...
(Date:12/10/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ) ... Market in Japan 2014-2018" report to their ... The integration of biometrics and smart ... upgradation of the driver,s license is one of ... the aforementioned projects, biometrics is being used as ...
(Date:12/3/2014)... , Dec. 2, 2014   Marvin Test ... innovative test solutions for military, aerospace, and manufacturing ... of its successful TS-900 PXI semiconductor test ... features of high-end systems to customers at a ... compared to traditional ATE. "Our ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... the new research results of the VTT Technical Research Centre ... of high-quality biofuels for the price of less than one ... the transfer of more than half the energy of wood ... for the construction of a commercial-scale production plant in Europe. ...
... Amsterdam, July 3, 2013 - Elsevier, a world-leading provider ... today announced the publication of a recent retrospective study ... better understand treatment considerations and outcomes for same-sex male ... The number of same-sex male couples and single ...
... has produced a potential new antibiotic which could help ... The potential new antibiotic targets a bacterial enzyme critical ... inhibitor which binds to the enzyme (called biotin protein ... of the bacteria. "Existing antibiotics target the bacterial ...
Cached Biology News:Gasification method turns forest residues to biofuel with less than a euro per liter 2Reproductive BioMedicine Online publishes study on assisted reproduction 2Novel chemistry for new class of antibiotic 2
... Series Multimode Detectors provide unmatched value ... application and automation needs. Capable of ... on the same instrument, the DTX ... or can be integrated seamlessly with ...
... Solution is available in a ready-to-use ... reagent for dewaxing paraffin-embedded tissue sections ... hybridization, or other analytical methods. The ... of dipping the slides in a ...
... The MJ Mini thermal cycler is a compact ... x 0.2 ml tubes, 12 x 0.5 ml ... heated lid uses a thumbwheel to adjust height ... oil-free cycling. Peltier heat pumps provide excellent thermal ...
MiniCycler thermal cycler with Hot Bonnet heated lid, holds 25x0.2ml tubes...
Biology Products: